Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway

EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis

(2013) Pingyu Zhang et al.   JOURNAL OF PATHOLOGY

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

(2013) S. K. Knutson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

(2012) Francesco Crea et al.   CANCER AND METASTASIS REVIEWS

MiR-155 Is a Liposarcoma Oncogene That Targets Casein Kinase-1  and Enhances  -Catenin Signaling

(2012) P. Zhang et al.   CANCER RESEARCH

Down-Regulation of the miR-25 and miR-30d Contributes to the Development of Anaplastic Thyroid Carcinoma Targeting the Polycomb Protein EZH2

(2012) Francesco Esposito et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

(2012) W. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

(2011) J. Zhou et al.   BLOOD

The role of EZH2 in tumour progression

(2011) C-J Chang et al.   BRITISH JOURNAL OF CANCER

3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells

(2011) Tetsuhiro Chiba et al.   INTERNATIONAL JOURNAL OF CANCER

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer

(2011) Francesco Crea et al.   Molecular Cancer

Down-Regulation of miR-101 in Endothelial Cells Promotes Blood Vessel Formation through Reduced Repression of EZH2

(2011) Michiel Smits et al.   PLoS One

Clinical significance of Polycomb gene expression in brain tumors

(2010) Francesco Crea et al.   Molecular Cancer

An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB

(2010) Junxia Min et al.   NATURE MEDICINE

Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas

(2010) J Braun et al.   ONCOGENE

MiR-30 family and EMT in human fetal pancreatic islets

(2010) Sabire Özcan   Islets

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways

(2009) Daniela Katz et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

(2009) T. B. Miranda et al.   MOLECULAR CANCER THERAPEUTICS

Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor

(2009) C. Y. Zou et al.   MOLECULAR CANCER THERAPEUTICS

A Double-Negative Feedback Loop between ZEB1-SIP1 and the microRNA-200 Family Regulates Epithelial-Mesenchymal Transition

(2008) C. P. Bracken et al.   CANCER RESEARCH

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

(2008) S.-M. Park et al.   GENES & DEVELOPMENT

The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional RepressorsZEB1andZEB2

(2008) Manav Korpal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

(2008) Q Cao et al.   ONCOGENE